BeyondSpring Names New Director After Lan Huang Resigns
BeyondSpring Inc. disclosed the resignation of founder and director Lan Huang effective June 3 2026 and the immediate election of a new board member. The change alters the company's board composition at a time when the clinical-stage biotech must continue meeting Nasdaq listing and SEC reporting obligations.
ecns.cnNEW YORK, June 4, 2026 — BeyondSpring Inc. reported the departure of Lan Huang from its board of directors and the election of a replacement director, according to an 8-K filed with the SEC on June 4.
The filing states that Huang resigned from the board effective June 3 2026. Item 5.02 identifies the action under “Departure or election of directors or principal officers.” The company simultaneously elected a new director whose term begins on the same date, restoring the board to its prior complement.
BeyondSpring, a developer of cancer therapies whose lead asset plinabulin has been the subject of multiple late-stage trials, now operates with an updated board responsible for oversight of clinical, regulatory and capital-raising activities. The 8-K does not disclose any disagreement between Huang and the company on matters of operations, policies or practices.
The board change triggers standard follow-on obligations. The company must ensure the new director completes any required Nasdaq independence and committee-assignment qualifications within the regulatory window and must reflect the update in its next proxy statement or Form 10-K.
Item 7.01 of the filing contains Regulation FD disclosure, indicating the company furnished the information to the market under fair-disclosure rules. Item 9.01 includes exhibits that attach the formal resignation letter and the board resolution electing the successor.
This marks the latest change in BeyondSpring’s governance roster. Huang co-founded the company and has served on the board since its inception; her exit removes the last founder-level director from day-to-day oversight while the company continues to manage cash runway and partnership discussions following earlier clinical readouts.
The Form 8-K constitutes the official SEC record. No further officer departures or executive-compensation adjustments were reported in the filing.
Coverage spread
Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.
No mainstream coverage of this story has surfaced yet.
Transparency
Related Stories
New York PostSpaceX Sets $135 IPO Price Ahead of Roadshow
SpaceX publicly set a $135 share price for its initial public offering, targeting a $75 billion raise that would value the company at $1.75 trillion. The company will begin its investor roadshow on Thursday with pricing expected June 11 and trading on Nasdaq the following day.
BenzingaAmericans Paid $53 Billion Extra for Fuel Since Iran War Began, Democratic Senator Says
A Democratic senator stated that U.S. households have spent $53 billion more on gas and diesel since the Iran war started. Treasury officials described the added inflation as a short-term blip. A separate congressional committee put the extra cost at $43 billion.
insidermonkey.comCoronado Global Resources Director Resigns as Shareholders Approve 2026 Compensation Plan
Coronado Global Resources Inc. disclosed the resignation of a board member and the results of its annual shareholder vote. The changes trigger mandatory SEC disclosures and reset the board's composition for the company's next fiscal reporting cycle.